What is ARS Pharmaceuticals, Inc.'s capex?

ARS Pharmaceuticals, Inc. (SPRY) reported capex of $0 in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s capex changed year-over-year?

ARS Pharmaceuticals, Inc.'s capex decreased by 100.0% year-over-year, from $91K to $0.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s capex?

Over 2 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s capex has grown at a 30.5% compound annual growth rate (CAGR), from $199K to $339K.

What does capex mean?

Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

ARS Pharmaceuticals, Inc. SPRY CapEx

CapEx at other companies

Amneal Pharmaceuticals, Inc.AMRX

$8.18M-37.9%

ViatrisVTRS

$39.9M-6.3%

AMP

Amphastar PharmaceuticalsAMPH

$9.51M-11.1%

Catalyst PharmaceuticalCPRX

$27K—

Eton Pharmaceuticals, Inc.ETON

$75K—

Other financials

Income statement

See full

Revenue$22.7M+184%

Operating income-$60.1M-61.8%

Net income-$60.6M-78.6%

EPS (diluted)-$0.61-74.3%

Balance sheet

See full

Cash & equivalents$24.3M-39.0%

Total debt$96.5M+132,122%

Total equity$61.3M-73.2%

Total assets$287.6M-12.1%

Cash flow

See full

Operating cash flow-$44.9M-10.3%

Free cash flow-$44.9M-10.1%

Valuation

See full

Market cap$1.05B-32.6%

Enterprise value$1.12B-26.0%

P/S10.6×-5.4×

Profitability

See full

Operating margin-204.5%—

Net margin-200%-219pp

FCF margin-177.1%-206pp

Returns & leverage

See full

Return on equity-136.4%-144pp

Debt / equity1.6×+1.6×

Current ratio4.9×-6.1×

Where this comes from

Reported directly by ARS Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about ARS Pharmaceuticals, Inc.'s capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s capex?: ARS Pharmaceuticals, Inc. (SPRY) reported capex of $0 in Q1 2026.
How has ARS Pharmaceuticals, Inc.'s capex changed year-over-year?: ARS Pharmaceuticals, Inc.'s capex decreased by 100.0% year-over-year, from $91K to $0.
What is the long-term trend for ARS Pharmaceuticals, Inc.'s capex?: Over 2 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s capex has grown at a 30.5% compound annual growth rate (CAGR), from $199K to $339K.
What does capex mean?: Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.